Alvotech and Abdi Ibrahim enter into an exclusive partnership for the development and commercialization of biosimilars in Turkey.
Alvotech and leading Turkish pharmaceutical company Abdi Ibrahim today announce that the two companies have entered into an exclusive partnership for the manufacturing and commercialization of Alvotech’s biosimilar portfolio for the Turkish market.
Under the partnership, Alvotech will be responsible for the development and joint supply of multiple high value biosimilar assets from its current product pipeline, while Abdi Ibrahim will be responsible for joint manufacturing from its own facility, along with the registration and commercialization of these assets in Turkey.
Alvotech‘s initial pipeline contains several biosimilar monoclonal antibodies and fusion proteins aimed at treating severe immune, inflammatory conditions, that improve the quality of life for patients around the world. Alvotech’s fully vertically integrated platform can support new products each year and over time create a substantial portfolio of high quality, high value products.
The partnership is based on shared values and a joint commitment to drive positive change for patients in Turkey. In partnering with Abdi Ibrahim, Alvotech will gain entry into Turkey’s fast-growing biosimilar market which has seen double digit growth during last years and will be one of the first company who has access to localization advantages through Abdi Ibrahim manufacturing capabilities. Abdi Ibrahim, established in 1912 and market leader since 2002 will use its strong local expertise while commercializing Alvotech’s portfolio through its largest sales and marketing organization in Turkish pharma industry.
Abdi Ibrahim is a privately-owned company who have kept a leading position in the Turkish pharmaceutical market for the last 17 years, operating in all therapeutic areas.
Today, Abdi Ibrahim manage a product portfolio exceeding 200 brands and 450 products which have been developed in our fully accredited R&D center and in-licensed. Manufacturing capabilities in Abdi İbrahim cover both chemical products and biologics with expansion to include hormone, sterile ophthalmology and sterile inhalation expected in 2019, with an Oncology production facility expected in 2021.
Abdi Ibrahim have maintained their position of strength in the Turkish market and increased their effectiveness in international markets, operating in 12 countries outside of Turkey and exporting their products to more than 60 countries worldwide.